Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Tumor-Agnostic 1Lymphoid 1Gastrointestinal 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Lymphoid 1

Interventions

Cytarabine 184Cyclophosphamide 176fludarabine 146Azacitidine 121venetoclax 115fludarabine phosphate 104Rituximab 80Decitabine 74Filgrastim 58Specimen Handling 55Etoposide 55Lenalidomide 47Biopsy 45Dexamethasone 41Methotrexate 40Bortezomib 40Mitoxantrone 39Granulocyte Colony-Stimulating Factor 39Daunorubicin 39Vincristine 37Melphalan 36ibrutinib 35Tacrolimus 35Dasatinib 34Whole-Body Irradiation 32Clofarabine 32Peripheral Blood Stem Cell Transplantation 31Mycophenolic Acid 31Injections 31Idarubicin 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × tozasertib × Other hematologic neoplasm × Clear all
NCT00111683 2015-08-25

MK0457 in Patients With Leukemia (0457-003)

Merck Sharp & Dohme LLC

Phase 1 Completed
28 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Lymphoid, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00500006 2015-01-30

A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)

Merck Sharp & Dohme LLC

Phase 1 Terminated
3 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡